Advertisement
Table 2 Treatment outcomes for patients treated with Artemether-Lumefantrine
| Clinical outcome | Total | Age group | |
|---|---|---|---|
| Initially selected | 122 | 28 ≤ 5 years | 94 > 5 years |
| Number of patients: n | |||
| PCR uncorrected responses | |||
| Withdrawn + Lost, n (%) | 19 (15.6) | 7 (25) | 12 (12.8) |
| Eligible; n (%) | 103 (100) | 21 (20.4) | 82 (79.6) |
| Global failure; n (%) | 10 (9.7) | 5 (23.8) | 5 (6.1) |
| ETF; n (%) | 1 (1 %) | 1 (4.8) | 0 |
| LCF; n (%) | 1 (1) | 0 | 1 (1.2) |
| LPF; n (%) | 8 (7.8) | 4 (19) | 4 (4.9) |
| ACPR; n (%) | 93 (90.3) | 16 (76.2) | 77 (94) |
| PCR corrected responses | |||
| Eligible; n (%) | 103 (100) | 21 (20.4) | 82 (78.6) |
| Global Failure; n (%) | 9 (8.7) | 5 (24) | 4 (5) |
| ACPR; n (%) | 94 (91.2) | 16 (76) | 78 (95) |
| Recrudescence; n (%) | 2 (1.9) | 1 (4.8) | 1 (1.2) |
| Reinfection; n (%) | 1 (1) | 0 | 1 (1.2) |
